Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Blood (2023) 141 (5): 481–489.

https://doi.org/10.1182/blood.2022017442

Published: 2023

Includes: Supplemental data

Journal Articles

Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy

Blood (2022) 140 (Supplement 1): 1867–1869.

https://doi.org/10.1182/blood-2022-156000

Published: 2022

Journal Articles

Effects of Severe Acute Graft-Versus-Host Disease on Quality of Life, Medical Comorbidities and Survival

Nahid Rashid, Albert Yeh, Marco Mielcarek, Masumi Ueda Oshima, Elizabeth F Krakow, Lynn E. Onstad, Laura Connelly-Smith, Phuong Vo, Stephanie J. Lee

Blood (2022) 140 (Supplement 1): 10552–10553.

https://doi.org/10.1182/blood-2022-167820

Published: 2022

Journal Articles

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Blood (2021) 138 (3): 273–282.

https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation

Danniel Zamora, Elizabeth R. Duke, Hu Xie, Bradley C. Edmison, Brenda Akoto, Richard Kiener, Terry Stevens-Ayers, Ralf Wagner, Marco Mielcarek, Wendy M. Leisenring, Keith R. Jerome, Joshua T. Schiffer, Greg Finak, Stephen C. De Rosa, Michael Boeckh

Blood (2021) 138 (1): 34–43.

https://doi.org/10.1182/blood.2020009396

Published: 2021

Includes: Supplemental data

Journal Articles

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Blood (2020) 135 (2): 97–107.

https://doi.org/10.1182/blood.2019003125

Published: 2020

Includes: Supplemental data

Journal Articles

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Blood (2019) 134 (Supplement_1): 4516.

https://doi.org/10.1182/blood-2019-127325

Published: 2019

Journal Articles

Comprehensive viromewide antibody responses by systematic epitope scanning after hematopoietic cell transplantation

Rachel A. Bender Ignacio, Sayan Dasgupta, Terry Stevens-Ayers, Tomasz Kula, Joshua A. Hill, Stephanie J. Lee, Marco Mielcarek, Ann Duerr, Stephen J. Elledge, Michael Boeckh

Blood (2019) 134 (6): 503–514.

https://doi.org/10.1182/blood.2019897405

Published: 2019

Includes: Supplemental data

Journal Articles

Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission

Colin Godwin, Jonathan R. Fromm, MD PhD, Brenda M. Sandmaier, MD, Marco Mielcarek, MD, Brent Wood, MD PhD, Frederick R. Appelbaum, MD, Rainer F. Storb, MD, Roland B. Walter, MD PhD MS

Blood (2018) 132 (Supplement 1): 5255.

https://doi.org/10.1182/blood-2018-99-117745

Published: 2018

Journal Articles

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Blood (2017) 129 (10): 1389–1393.

https://doi.org/10.1182/blood-2016-09-737825

Published: 2017

Includes: Supplemental data

Journal Articles

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

Brenda M Sandmaier, MD, David G Maloney, MD PhD, Barry E. Storer, PhD, Gitte Olesen, MD, Michael B. Maris, MD, Jonathan A Gutman, MD, Soren Lykke Petersen, MD DMSC, Amelia Langston, MD, Thomas Chauncey, Wolfgang Bethge, MD, Michael A Pulsipher, MD, Brian Thomas Kornblit, MD PhD, Ann E Woolfrey, MD, Marco Mielcarek, MD, Paul J. Martin, MD, Mary E.D. Flowers, MD, Rainer F. Storb, MD

Blood (2016) 128 (22): 506.

https://doi.org/10.1182/blood.V128.22.506.506

Published: 2016

Journal Articles

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

Marco Mielcarek, Terry Furlong, Paul V. O’Donnell, Barry E. Storer, Jeannine S. McCune, Rainer Storb, Paul A. Carpenter, Mary E. D. Flowers, Frederick R. Appelbaum, Paul J. Martin

Blood (2016) 127 (11): 1502–1508.

https://doi.org/10.1182/blood-2015-10-672071

Published: 2016

Includes: Supplemental data

Journal Articles

A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience

Huiying Qiu, MD, Brenda M. Sandmaier, MD, Barry E. Storer, PhD, Thomas Chauncey, MD PhD, Finn Petersen, MD, Michael A. Pulsipher, Benedetto Bruno, MD, Mary Flowers, MD, Marco Mielcarek, MD, Rainer Storb, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 1949.

https://doi.org/10.1182/blood.V126.23.1949.1949

Published: 2015

Journal Articles

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Daisuke Araki, MD, Brent L Wood, MD PhD, Megan Othus, PhD, Jerald P. Radich, MD, Anna B. Halpern, MD, Yi Zhou, MD PhD, Marco Mielcarek, MD, Elihu H. Estey, MD, Frederick R. Appelbaum, MD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 2571.

https://doi.org/10.1182/blood.V126.23.2571.2571

Published: 2015

Journal Articles

Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation

Yi Zhou, MD PhD, Daisuke Araki, MD, Megan Othus, PhD, Jerald P. Radich, MD, Anna B. Halpern, MD, Marco Mielcarek, MD, Elihu H. Estey, MD, Brent L. Wood, MD PhD, Frederick R. Appelbaum, MD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 173.

https://doi.org/10.1182/blood.V126.23.173.173

Published: 2015

Journal Articles

Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation

Marco Mielcarek, MD, Terrence Furlong, Paul V. O'Donnell, MD PhD, Barry E. Storer, PhD, Rainer F. Storb, MD, Paul A. Carpenter, MD, Paul J. Martin, MD

Blood (2014) 124 (21): 1161.

https://doi.org/10.1182/blood.V124.21.1161.1161

Published: 2014

Journal Articles

The Effect Of Donor and Recipient Statin Treatment On Infections After Allogeneic Hematopoietic Cell Transplantation

Sachiko Seo, MD, Michael Boeckh, MD, Barry E. Storer, PhD, Mark M Schubert, DDS, MSD, Marcello Rotta, MD, Brenda M. Sandmaier, MD, Marco Mielcarek, MD

Blood (2013) 122 (21): 4548.

https://doi.org/10.1182/blood.V122.21.4548.4548

Published: 2013

Journal Articles

Post-Transplantation Cyclophosphamide Following Busulfan and Fludarabine Myeloablative Conditioning Prevents Severe Acute and Chronic Graft-Versus-Host Disease and Minimizes Duration Of Immunosuppression: Results Of a Multi-Institutional Trial In Patients With High-Risk Hematologic Malignancies

Christopher G. Kanakry, MD, Paul O’Donnell, MD, PhD, Terry Furlong, NP, Marcos J de Lima, MD, Wei Wei, MS, Marta Medeot, MD, Marco Mielcarek, MD, Richard E Champlin, MD, Richard J. Jones, Peter F. Thall, PhD, Borje S. Andersson, MD, PhD, Leo Luznik

Blood (2013) 122 (21): 3310.

https://doi.org/10.1182/blood.V122.21.3310.3310

Published: 2013

Journal Articles

Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial

Marco Mielcarek, MD, Terrence Furlong, Barry E. Storer, PhD, Margaret L. Green, MD, Paul A. Carpenter, MD, George B McDonald, MD, Mary E. D. Flowers, MD, Rainer Storb, MD, Frederick R. Appelbaum, MD, Michael Boeckh, MD, Paul J. Martin, MD

Blood (2013) 122 (21): 703.

https://doi.org/10.1182/blood.V122.21.703.703

Published: 2013

Journal Articles

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

Margaret L. Green, Wendy M. Leisenring, Hu Xie, Roland B. Walter, Marco Mielcarek, Brenda M. Sandmaier, Stanley R. Riddell, Michael Boeckh

Blood (2013) 122 (7): 1316–1324.

https://doi.org/10.1182/blood-2013-02-487074

Published: 2013

Includes: Supplemental data

NARROW

Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy

Effects of Severe Acute Graft-Versus-Host Disease on Quality of Life, Medical Comorbidities and Survival

HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis

Cytomegalovirus-specific T-cell reconstitution following letermovir prophylaxis after hematopoietic cell transplantation

Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial

Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizumab, in Subjects with Newly Diagnosed Acute Graft Versus Host Disease

Comprehensive viromewide antibody responses by systematic epitope scanning after hematopoietic cell transplantation

Pre-Transplant Monocytic Myeloid-Derived Suppressor Cell Frequency Has No Prognostic Role for Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Remission

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Is It Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation

Posttransplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after HLA-Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation

The Effect Of Donor and Recipient Statin Treatment On Infections After Allogeneic Hematopoietic Cell Transplantation

Post-Transplantation Cyclophosphamide Following Busulfan and Fludarabine Myeloablative Conditioning Prevents Severe Acute and Chronic Graft-Versus-Host Disease and Minimizes Duration Of Immunosuppression: Results Of a Multi-Institutional Trial In Patients With High-Risk Hematologic Malignancies

Efficacy and Safety Of Lower-Dose Glucocorticoids For Initial Treatment Of Acute Graft-Versus-Host Disease: A Randomized Controlled Trial

CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only